Director Share Purchase

Graft Polymer (UK) PLC

16 May 2023

 

16 May 2023

Graft Polymer (UK) Plc

("Graft Polymer", the "Company", and together with its subsidiaries, the "Group")

Director Share Purchase

Graft Polymer (UK) Plc, a business focused on the development and commercial production of modified polymer solutions including additives, alloys, synthesis, and drug delivery systems, announces that on 15 May 2023, Alex Brooks, Non-Executive Director of Graft Polymer, acquired 56,399 Ordinary Shares at an average price of 4.6 pence per Ordinary Share.  Following this acquisition of shares, Alex Brooks has a total beneficial interest in 475,004 Ordinary Shares, representing approximately 0.46% of the total issued share capital of the Company.

 -Ends-

Authorised for release by the board of directors, for further information please contact:

Graft Polymer (UK) Plc (via St Brides Partners)	St Brides Partners (Public Relations)
Roby Zomer, Non Executive Chairman Yifat Steuer, CFO and Executive Director https://www.graftpolymer.com	Catherine Leftley Ana Ribeiro Max Bennett [e-mail]
Turner Pope Investments (Broker)
James Pope Andy Thacker [phone]

About Graft Polymer

Graft Polymer is a London Stock Exchange listed company (GPL.L) with a cutting-edge, cash-flow positive, research and development (R&D) and manufacturing facility based in Slovenia which has already introduced more than 50 products to the market. The core business of the Group comprises polymer modification and drug delivery system developments. The Group has developed a proprietary set of polymer modification technologies which uses recycled raw materials and a closed loop system to reduce waste. Graft Polymer's technology can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.

Graft Polymer has two divisions: the first division focusses on polymer modification; the second is GraftBio which develops IP for Bio/Pharma applications (including a drug delivery system to support and provide solutions to the market, which had been heavily impacted by the COVID-19 pandemic). A significant milestone was reached in May 2022 when the Slovenian manufacturing facility was granted a Hazard Analysis and Critical Control Point (HACCP) Certificate.

Environment, Social and Governance is at the forefront of the Group's strategy and the facility in Slovenia has been granted ISO 14001 accreditation in recognition of the environmental management systems in place to reduce waste. Graft Polymer only uses REACH and ROHS certificated raw materials instead of toxic raw materials, and its extensive R&D programme has also developed specialised recycling polymer additives which increases the strength of recycled blends and plastic products whilst also reducing plastic waste by between 40 and 50 per cent.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Alex Brooks
2	Reason for the notification
a)	Position/status	Non-Executive Director of Graft Polymer (UK) Plc
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Graft Polymer (UK) Plc
b)	LEI	2138005PH7OJRCRPUD88
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares
	Identification code	GB00BMD1Z199
b)	Nature of the transaction	On market purchase of shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			4.6p	56,399
d)	Aggregated information
		N/A Single Transaction
	- Aggregated volume
	- Price
e)	Date of the transaction	15 May 2023
f)	Place of the transaction	London Stock Exchange

 

END